New Insights Into HIV-1 Vaccine Design
News Sep 21, 2015
Scientists at Los Alamos National Laboratory have created a computational model that could change the way that researchers look at possibilities for an HIV-1 vaccine.
“An effective HIV-1 vaccine has proven elusive, partly due to the difficulty of causing an immune response that can neutralize the diverse viral strains circulating in the human population,” said Alan Perelson, of Los Alamos’ Theoretical Biology and Biophysics group. “Harnessing the power of broadly neutralizing antibodies, which emerge years into a chronic HIV infection, could help overcome this challenge.”
Shishi Luo and Perelson, published their findings in the paper “Competitive exclusion by autologous antibodies can prevent broad HIV-1 antibodies from arising.”
They used a mathematical model to examine how broadly neutralizing antibodies coevolve with HIV. By simulating the co-evolution of multiple viral strains and antibody populations, Perelson and Luo show that broadly neutralizing antibodies emerge late in infection due to competition from the highly specific antibody response to the dominant viral species in an infected person.
In their model, broadly neutralizing antibodies emerge earlier, and face less competition, in infections caused by multiple distinct strains of HIV compared with single strains. The findings support the view that a vaccine containing a mixture of diverse viral strains might reduce this competition, reduce the number of antibody mutations and elicit broadly neutralizing antibodies earlier in infection.
Traditional vaccine design is based on the premise that infection is protective and that a vaccine should mimic a natural infection. However, Luo and Perelson’s findings suggest that a vaccine should instead present the host with high levels of multiple diverse strains.
Calidi Biotherapeutics, Inc. Announces its Corporate Vision in Groundbreaking Cancer Drug DevelopmentNews
Calidi Biotherapeutics, Inc., formerly StemImmune, Inc., a clinical‐stage biotherapeutics company at the forefront of oncolytic virus-based immunotherapies for cancer, announced a focused effort to advance its oncolytic virus drug development.READ MORE
Bicycle Therapeutics Expands Strategic Partnership with AstraZenecaNews
New programs added in respiratory and cardio-metabolic diseases.READ MORE
Worldwide Clinical Trials Receives 2018 CRO Leadership AwardsNews
Life Science Leader and Industry Standard Research assess 70 contract research organizations, honoring Worldwide Clinical Trials for fifth consecutive year.READ MORE